Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,878 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J, Zhang M, Liu J, Liu Z, Shen P, Nie L, Guo W, Cai D, Liu J, Armstrong CM, Sun G, Chen J, Zhu S, Dai J, Zhang H, Zhao P, Zhang X, Yin X, Zhu X, Ni Y, Chen N, Zeng H. Zhao J, et al. Among authors: zeng h. Prostate. 2019 Sep;79(13):1553-1562. doi: 10.1002/pros.23875. Epub 2019 Jul 11. Prostate. 2019. PMID: 31294486
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Wang Z, Zhu S, Zhao J, Nie L, Chen X, Zhang M, Chen N, Sun G, Chen J, Ni Y, Dai J, Liu Z, Tao R, Zhang X, Zhu X, Zhang H, Liang J, Wang Z, He B, Shen P, Zeng H. Wang Z, et al. Among authors: zeng h. Prostate. 2021 Nov;81(15):1191-1201. doi: 10.1002/pros.24215. Epub 2021 Aug 26. Prostate. 2021. PMID: 34435696 Free PMC article.
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
Xu N, Zhao J, Zhao F, Liu H, Yin W, Zhu S, Nie L, Sun G, Zheng L, Liu Z, Cai D, Chen J, Dai J, Ni Y, Wang Z, Zhang X, Liang J, Chen Y, Hu X, Pan X, Yin X, Zhu X, Zhang Y, Wang Z, Zeng Y, Wang M, Shen P, Chen N, Zeng H. Xu N, et al. Among authors: zeng h, zeng y. J Cancer Res Clin Oncol. 2023 Aug;149(10):7247-7258. doi: 10.1007/s00432-023-04639-9. Epub 2023 Mar 13. J Cancer Res Clin Oncol. 2023. PMID: 36907910
8,878 results